CD5 and B-cell chronic lymphocytic leukemia: However, it is still very important to develop alternative PCD approaches that kill specifically the malignant CLL cells, including those in high-risk individuals, while sparing the residual CD5− B lymphocytes and the T cells of the CLL patient.